Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lenalidomide

- PMLiVE

Takeda’s HyQvia receives EC approval for rare neuromuscular disorder CIDP

HyQvia can now be used as a maintenance therapy for patients of all ages with CIDP

- PMLiVE

BMS announces CHMP recommendation for multiple myeloma therapy Abecma

More than 50,000 cases of the blood cancer are diagnosed in Europe every year

- PMLiVE

NICE recommends two AI-powered software tools for stroke diagnosis in NHS

Brainomix's e-Stroke and Ischemaview’s RapidAI were reported by the health technology assessment agency to improve access to treatment for stroke patients

- PMLiVE

Pfizer’s Talzenna recommended by NICE for advanced breast cancer

An estimated 300 patients will be eligible for treatment with the PARP inhibitor

- PMLiVE

Takeda’s HyQvia granted FDA approval to treat rare neuromuscular disorder CIDP

Approximately five to seven people per 100,000 in the US are affected by the disorder

- PMLiVE

Pfizer’s COVID-19 antiviral Paxlovid recommended by NICE for expanded use

The latest guidance will mean an estimated 5.3 million people will be eligible to access Paxlovid

- PMLiVE

Bristol Myers Squibb’s Opdualag recommended by NICE for advanced melanoma

More than 16,700 new cases of melanoma are diagnosed in the UK every year

- PMLiVE

AstraZeneca/Merck’s Lynparza recommended by NICE for advanced prostate cancer

The combination therapy has been recommended for patients regardless of biomarker status

- PMLiVE

Pfizer’s Elrexfio granted EC approval for relapsed and refractory multiple myeloma

More than 50,000 cases of the blood cancer are diagnosed each year in Europe

- PMLiVE

AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer

Approximately 7,400 new cases of the disease are diagnosed in the UK every year

- PMLiVE

GSK shares positive phase 3 results for Blenrep combination in multiple myeloma

Approximately 176,000 new cases of multiple myeloma are diagnosed globally each year

- PMLiVE

AstraZeneca’s rare disease unit receives NICE recommendation for Wolman disease therapy in infants

The enzyme replacement therapy will become the first treatment available on the NHS for the rare genetic disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links